RNA Access: Take advantage of Moderna's mRNA platform for global health

The Institut Pasteur and Moderna have signed a Master Material Transfer Agreement (MMTA) to enable researchers of the Institut Pasteur to have access to Moderna's preclinical manufacturing capabilities and its research and development expertise.

The objective is to jointly explore the possibility of mRNA to tackle the world's greatest global public health threats.

The program is dedicated to Institut Pasteur researchers interested in using Moderna mRNA production capabilities to explore novel antigen designs and accelerate vaccines development.

Moderna has provided a list of its high priority research activities (see it in Annex) but the list is not exhaustive and other pathogens could be targeted if belonging to the field of the top-level expertise of the researcher team.

In the framework of the MMTA, the access to the pre-clinical mRNA production is free of charge for Institut Pasteur researchers. The shipping time is between 6 to 8 weeks after the order and validation of the protocol.

If the eligibility criteria are met, all projects can be accepted, throughout the year.

On Wednesday May 20, a first list of researchers will be transferred to Moderna, which will allow them access to the Moderna web platform. Each Institut Pasteur researcher could then drop its amino-acid sequence and the protocol of its research project on this platform to be validated by Moderna’s team, before mRNA production and shipping.

Concretely, every researcher interested should contact Valérie Hélin, the person in charge of the Alliance management with Moderna at the Department of Technology Transfer and Industrial Partnership (Darri): valerie.helin@pasteur.fr

Valérie Helin will provide you all information regarding protocol, support from Moderna and other terms of the MMTA.